Strategies for managing cytomegalovirus in transplant recipients (Q37773992)

23 August 2017

1 reference

title

Strategies for managing cytomegalovirus in transplant recipients (English)

1 reference

23 August 2017

0 references

Raymund R Razonable

1

1 reference

PubMed ID

20642369

23 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

1 reference

23 August 2017

11

1 reference

23 August 2017

12

1 reference

23 August 2017

1983-1997

1 reference

Definitions of cytomegalovirus infection and disease in transplant recipients

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Delayed-onset primary cytomegalovirus disease after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Association of cytomegalovirus genotype with graft rejection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Glomerulopathy Associated with Cytomegalovirus Viremia in Renal Allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Cytomegalovirus infection and new-onset post-transplant diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Human beta-herpesvirus interactions in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

The pathogenesis of hepatitis C virus is influenced by cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Relevance of Toll-like receptor-4 polymorphisms in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

The R753Q polymorphism abrogates toll-like receptor 2 signaling in response to human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

The dynamics of human cytomegalovirus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Dynamics of Cytomegalovirus Replication during Preemptive Therapy with Oral Ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Interlaboratory comparison of cytomegalovirus viral load assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Antimicrobial strategies in the care of organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Late and atypical cytomegalovirus disease in solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Clinical features and outcomes of cytomegalovirus retinitis after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Ganciclovir-resistant cytomegalovirus in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Primary cytomegalovirus disease after five years of antiviral prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Immune-based therapies for cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Vaccine prevention of maternal cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

The Influence of Innate Immunity Gene Receptors Polymorphisms in Renal Transplant Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Interrelationships among Quantity of Human Cytomegalovirus (HCMV) DNA in Blood, Donor‐Recipient Serostatus, and Administration of Methylprednisolone as Risk Factors for HCMV Disease following Liver Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

Human Cytomegalovirus (HCMV) Replication Dynamics in HCMV‐Naive and ‐Experienced Immunocompromised Hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.492395

10.1517/14656566.2010.492395

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20642369